Two Massachusetts biotech startups working on potential cancer treatments said Friday that they have made deals to collaborate with Celgene (CELG), the drug maker being acquired in one of the biggest pharmaceutical mergers ever.

Kyn Therapeutics, a Boston biotech, said it has signed an agreement with Celgene to develop immuno-oncology medicines. Kyn will receive an upfront cash payment of $80 million and an equity investment from Celgene, which will get exclusive options to license two drug development programs. Kyn is eligible for additional payments if it reaches specified goals for developing and marketing new medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy